非布司他联合血液透析治疗慢性肾脏病的疗效及对患者炎症因子水平、肾功能的影响

doi:10.3969/j.issn.1671-7171.2024.01.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1244 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨非布司他联合血液透析(HD)治疗慢性肾脏病(CKD)的临床疗效及对患者炎症因子水平、肾功能的影响。【方法】在本院接受规律HD的98例CKD患者,随机分为透析组(采用HD治疗)和联合组(非布司他联合HD治疗),每组49例。比较两组患者的疗效,治疗前后炎症因子水平、肾功能、血脂及氧化应激指标的变化及安全性。【结果】联合组治疗后纤溶酶原激活物抑制因子-1(PAI-1)、肿瘤坏死因子-α(TNF-α)、脂联素、尿酸、血清肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量、β₂-微球蛋白(β₂-MG)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、丙二醛(MDA)均低于透析组(P<0.05),肾小球滤过率(eGFR)、高密度脂蛋白胆固醇(HDL-C)、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GSH-Px)均高于透析组(P<0.05);联合组临床总有效率高于透析组(P<0.05);两组治疗前后血常规、肝功能均无明显异常,未发现过敏反应、药物不耐受及严重毒副反应。【结论】非布司他联合HD治疗可改善CKD患者肾功能及临床疗效,减轻炎症反应、氧化应激反应,降低血脂水平,且安全性高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杜闻闻

关键词 ：肾疾病, 慢性病, 肾透析, 抗痛风药/治疗应用, 治疗结果

Abstract：【Objective】 To observe the clinical efficacy of nifedipine combined with hemodialysis in the treatment of chronic kidney disease (CKD),and effects on inflammation levels and renal function. 【Methods】 A total of 98 CKD patients who received regular hemodialysis(HD) in our hospital were randomly divided into the dialysis group (HD treatment) and the combined group (nifedipine combined with HD treatment), with 49 cases in each group. The levels of inflammatory factors, renal function, blood fat and oxidative stress indicators before and after treatment were compared between the two groups. The clinical efficacy and safety of the two groups were compared as well. 【Results】 After treatment, the levels of plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), adiponectin, uric acid, serum creatinine (Scr), urea nitrogen (BUN), 24 h urine protein quantification, β₂-microglobulin (β₂-MG), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), malondialdehyde (MDA) in the combined group were lower than those in the dialysis group (P<0.05), while the glomerular filtration rate (eGFR), high-density lipoprotein cholesterol (HDL-C), catalase (CAT), glutathione peroxidase (GSH-Px) were higher than those in the dialysis group (P<0.05). The total effective rate of the combined group was higher than that of the dialysis group (P<0.05). There were no significant abnormality in blood routine and liver function before and after treatment in both groups, and no allergic reaction, drug intolerance or serious adverse reaction were found. 【Conclusion】 Nifedipine combined with HD can improve renal function and clinical efficacy of CKD patients, reduce inflammatory response and oxidative stress, reduce blood fat, and has high safety.

Key words： Kidney Diseases Chronic Disease Renal Dialysis Gout Suppressants/TU Treatment Outcome

收稿日期: 2023-08-31

中图分类号:

R692

引用本文:

杜闻闻. 非布司他联合血液透析治疗慢性肾脏病的疗效及对患者炎症因子水平、肾功能的影响[J]. 医学临床研究, 2024, 41(1): 70-73.
DU Wenwen. Effect of Nifedipine Combined with Hemodialysis on Inflammation Level and Renal Function in Patients with Chronic Kidney Disease. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 70-73.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.01.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I1/70

[1] LI X, LINDHOLM B. Cardiovascular risk prediction in chronic kidney disease[J].Am J Nephrol,2022, 53(10):730-739.
[2] BROWN E A, ZHAO J, MCCULLOUGH K, et al. Burden of kidney disease, health-related quality of life, and employment among patients receiving peritoneal dialysis and in-center hemodialysis: findings from the DOPPS program[J].Am J Kidney Dis,2021, 78(4):489-500.
[3] NISHIZAWA H, MAEDA N, SHIMOMURA I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease[J].Hypertens Res,2022, 45(4):635-640.
[4] GAO L G, WANG B, PAN Y, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis[J].Clin Cardiol,2021, 44(7):907-916.
[5] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查,诊断及防治指南(2022年版)[J].中华肾脏病杂志, 2022, 38(5):453-464.
[6] JOHNSON R J, SANCHEZ LOZADA L G, LANASPA M A, et al. Uric acid and chronic kidney disease: still more to do[J].Kidney Int Rep,2022, 8(2):229-239.
[7] HASSAN W, SHRESTHA P, SUMIDA K, et al. Association of uric acid-lowering therapy with incident chronic kidney disease[J].JAMA Netw Open,2022, 5(6):e2215878.
[8] COHEN C, LE GOFF O, SOYSOUVANH F, et al. Glomerular endothelial cell senescence drives age-related kidney disease through PAI-1[J].EMBO Mol Med,2021, 13(11):e14146.
[9] COIMBRA S, ROCHA S, VALENTE MJ, et al. New insights into adiponectin and leptin roles in chronic kidney disease[J].Biomedicines,2022, 10(10):2642.
[10] FENG J N, YU L, LI H, et al. High serum β₂-microglobulin is a significant predictor of mortality in maintenance hemodialysis patients[J].Semin Dial,2023, 36(3):247-254.
[11] EBERT T, NEYTCHEV O, WITASP A, et al. Inflammation and oxidative stress in chronic kidney disease and dialysis patients[J].Antioxid Redox Signal,2021, 35(17):1426-1448.
[12] MIURA T, SAKUYAMA A, XU L, et al. Febuxostat ameliorates high salt intake-induced hypertension and renal damage in Dahl salt-sensitive rats[J].J Hypertens,2022, 40(2):327-337.
[13] YANG H T, LI R, LI Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China[J].Int Urol Nephrol,2023, 55(5):1343-1352.